发明名称 |
Transthyretin variants |
摘要 |
The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life. |
申请公布号 |
US8633153(B2) |
申请公布日期 |
2014.01.21 |
申请号 |
US20090380451 |
申请日期 |
2009.02.26 |
申请人 |
WALKER KENNETH WILLIAM;XIONG FEI;AMGEN INC. |
发明人 |
WALKER KENNETH WILLIAM;XIONG FEI |
分类号 |
A61K38/02;C12N15/09;A61K38/00;A61K38/16;A61K38/17;A61K38/44;A61K47/32;A61K47/34;A61K47/36;A61K47/42;A61K47/48;A61P3/10;A61P7/04;C07K14/435;C07K14/475;C07K14/605;C07K17/08;C07K19/00 |
主分类号 |
A61K38/02 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|